Tarsus Pharmaceuticals, Inc. Income Statement
TARS / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Tarsus Pharmaceuticals, Inc. reported $451M in revenue and $66M in net loss for FY2025. Revenue has grown at a 67.7% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $451.4M | $183.0M | $17.4M | $57.0M | $57.0M | $0 | - | - |
| SG&A Expense | $427.3M | $237.3M | $108.7M | $25.4M | $25.4M | $8.2M | $1.1M | - |
| R&D Expense | $64.3M | $53.4M | $50.3M | $41.7M | $41.7M | $18.8M | $3.2M | - |
| Operating Income | -$71.0M | -$120.6M | -$143.2M | -$12.2M | -$12.2M | -$27.0M | -$4.3M | - |
| Interest Expense | $8.9M | $7.8M | $3.3M | $0 | $0 | - | - | - |
| Income Tax | $2.1M | $0 | $0 | $55.0K | $55.0K | $1.0K | $1.0K | - |
| Net Income | -$66.4M | -$115.6M | -$135.9M | -$13.8M | -$13.8M | -$26.8M | -$4.7M | -$1.3M |
| EPS (Basic) | -$4.62 | -$2.52 | -$2.52 | -$0.67 | -$4.32 | -$4.32 | - | - |
| EPS (Diluted) | -$4.62 | -$2.52 | -$2.52 | -$0.67 | -$4.32 | -$4.32 | - | - |
| Shares Outstanding | 38.3M | 34.2M | 26.7M | 20.7M | 20.3M | 6.2M | 2.4M | - |
| Operating Margin | -15.7% | -65.9% | -820.5% | -21.3% | -21.3% | - | - | - |
| Profit Margin | -14.7% | -63.2% | -778.9% | -24.3% | -24.3% | - | - | - |